MicroRNA-141 Inhibits Cell Proliferation and Invasion and Promotes Apoptosis by Targeting Hepatocyte Nuclear Factor-3β in Hepatocellular Carcinoma Cells
Overview
Authors
Affiliations
Background: Hepatocyte nuclear factor-3β (HNF-3β) plays a critical role in hepatocyte differentiation and controls liver-specific gene expression during the development of hepatocellular carcinoma (HCC), but the molecular basis of this process has not been fully elucidated. microRNAs (miRNAs) are powerful, post-transcriptional regulators of gene expression. Whether miRNAs can impact the effects of HNF-3β in HCC is still unknown.
Methods: HNF-3β and miR-141 expression levels were detected in HepG2 cells, using real-time quantitative RT-PCR (qRT-PCR). Luciferase reporter assays and Western blots were used to validate HNF-3β as a direct target gene of miR-141. Cell proliferation, invasion, and apoptosis were also examined to confirm whether miR-141 could impact on HNF-3β in HCC.
Results: In this study, we found that HNF-3β protein levels were consistently upregulated in HCC clinical tissues compared with matched normal adjacent tissues. However, the mRNA levels of HNF-3β varied in random tissues, suggesting that a post-transcriptional mechanism was involved in its regulation. We used bioinformatic analyses to search for miRNAs that could potentially target HNF-3β, and identified specific targeting sites for miR-141 in the 3'-untranslated region (3'-UTR) of the HNF-3β gene. By overexpressing miR-141 in HepG2 cells, we experimentally validated that miR-141 directly regulated HNF-3β expression. Furthermore, the biological consequences of targeting HNF-3β by miR-141 were examined using cell proliferation, invasion and apoptosis assays in vitro. We demonstrated that the repression of HNF-3β by miR-141 suppressed the proliferation and invasion and promoted the apoptosis of HepG2 cells.
Conclusions: miR-141 functions as a tumor suppressor in HCC cells through the inhibition of HNF-3β translation.
Baghermanesh S, Barati M, Hosseini A PLoS One. 2024; 19(8):e0309289.
PMID: 39196911 PMC: 11355560. DOI: 10.1371/journal.pone.0309289.
Hao Z, Yin C, Wang X, Huo Z, Zhang G, Jiang D Heliyon. 2023; 9(11):e21549.
PMID: 38027809 PMC: 10656251. DOI: 10.1016/j.heliyon.2023.e21549.
Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment.
Song J, Zhou H, Gu D, Xu Y Front Oncol. 2022; 11:790358.
PMID: 35096588 PMC: 8790246. DOI: 10.3389/fonc.2021.790358.
Ma L, Shao H, Chen H, Deng Q J Oncol. 2021; 2021:5425491.
PMID: 34675977 PMC: 8526259. DOI: 10.1155/2021/5425491.
Huang H, Wang Y, Huang T, Wang L, Liu Y, Wu Q J Physiol Biochem. 2021; 77(4):625-638.
PMID: 34291417 DOI: 10.1007/s13105-021-00829-6.